Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
Hurthle cell tumors: applying molecular markers to define a new management algorithm Maxwell EL; Palme CE; Freeman JArch Otolaryngol Head Neck Surg 2006[Jan]; 132 (1): 54-8OBJECTIVE: To design a new management algorithm for all Hurthle cell tumors and variants based on histopathologic findings and the ret/PTC molecular marker. DESIGN: A retrospective medical record review. SETTING: A large tertiary care teaching center. PATIENTS: Forty-five consecutive cases of Hurthle cell carcinoma were gathered from a database of 661 patients with well-differentiated epithelial thyroid cancers compiled over 22 years. Data collected included patient information, tumor information, and treatment factors. MAIN OUTCOME MEASURES: Outcome parameters included tumor and treatment variables, which were analyzed statistically using the chi(2) and t tests. Disease-free survival and disease-specific survival analyses were performed using Kaplan-Meier analysis. RESULTS: A female-male ratio of 3:1 was found, with a median patient age of 57 years. Twenty-three patients had American Joint Commission on Cancer stage II disease. Treatment factors had no significant effect on disease recurrence or survival. More than half of the patients had histologically proved regional metastases. Vascular invasion significantly diminished disease-specific survival and disease-free interval. CONCLUSIONS: We found a high incidence of Hurthle cell carcinoma with cervical metastasis. On the basis of findings of this study and our previous clinical and molecular findings, we propose a treatment algorithm that combines histologic examination and molecular assays for the ret/PTC gene rearrangements specific to papillary thyroid carcinoma. After permanent section analysis demonstrating Hurthle cell metaplasia, the algorithm mandates completion thyroidectomy in patients with ret/PTC-positive Hurthle cell tumors and clinical observation for ret/PTC-negative Hurthle cell adenomas. We recommend more aggressive treatment of ret/PTC-positive Hurthle cell lesions (or Hurthle cell papillary thyroid cancer), because of the higher incidence of regional metastatic disease.|*Algorithms[MESH]|*Neck Dissection[MESH]|*Thyroidectomy[MESH]|Adenoma, Oxyphilic/*metabolism/pathology/radiotherapy/surgery[MESH]|Adult[MESH]|Aged[MESH]|Aged, 80 and over[MESH]|Biomarkers, Tumor/*metabolism[MESH]|Decision Making[MESH]|Disease-Free Survival[MESH]|Female[MESH]|Follow-Up Studies[MESH]|Humans[MESH]|Male[MESH]|Middle Aged[MESH]|Neoplasm Staging[MESH]|Oncogene Proteins, Fusion/*metabolism[MESH]|Protein-Tyrosine Kinases/*metabolism[MESH]|Radiotherapy, Adjuvant[MESH]|Retrospective Studies[MESH]|Thyroid Neoplasms/*metabolism/pathology/radiotherapy/surgery[MESH]|Treatment Outcome[MESH] |
